Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia

Haematologica

Volumn 98, Issue 1, 2013, Pages 107-113

  Kar, Sarah Abu ^a   Jankowska, Anna ^a   Makishima, Hideki ^a   Visconte, Valeria ^a   Jerez, Andres ^a   Sugimoto, Yuka ^a   Muramatsu, Hideki ^b   Traina, Fabiola ^c   Afable, Manuel ^d   Guinta, Kathryn ^a   Tiu, Ramon V ^a,d   Przychodzen, Bartlomiej ^a   Sakaguchi, Hirotoshi ^b   Kojima, Seiji ^b   Sekeres, Mikkael A ^d   List, Alan F ^e   McDevitt, Michael A ^f   Maciejewski, Jaroslaw P ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1;

ADULT; AGED; ARTICLE; CANCER STAGING; CHRONIC MYELOMONOCYTIC LEUKEMIA; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; SF3B1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICEOSOME; SRSF2 GENE; U2AF1 GENE;

ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SPLICEOSOMES;

EID: 84872085802     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.064048     Document Type: Article

References (40)

1. Bacher U, Haferlach T, Schnittger S, Kreipe H, Kroger N. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol. 2011;153(2):149-67.
2. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation-UTX, EZH2 AND DNMT3A. Blood. 2011; 118(14):3932-41.
3. Kohlmann A, Grossmann V, Klein H-U, Schindela S, Weiss T, Kazak B, et al. Nextgeneration sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia (CMML) by detecting frequent alterations in TET2, CBL, RAS and RUNX1. J Clin Oncol. 2010;28(24):3858-65.
4. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2011;26(3):542-5.
5. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478 (7367):64-9.
6. Makishima H, Visconte V, Sakaguchi H, Abu Kar S, Jankowska AM, Jerez A, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012;119(14):3203-10.
7. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365(15):1384-95.
8. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012; 44(1):47-52.
9. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011;118(26):6904-8.
10. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365(26):2497-506.
11. Gama-Carvalho M, Krauss RD, Chiang L, Valcarcel J, Green MR, Carmo-Fonseca M. Targeting of U2AF65 to sites of active splicing in the nucleus. J Cell Biol. 1997;137 (5):975-87.
12. Shen H, Kan JL, Green MR. Arginine-serine-rich domains bound at splicing enhancers contact the branchpoint to promote prespliceosome assembly. Mol Cell. 2004;13(3):367-76.
13. Folco EG, Coil KE, Reed R. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev. 2011;25(5):440-4.
14. Shepard PJ, Hertel KJ. The SR protein family. Genome Biol. 2009;10(10):242.
15. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
16. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002; 99(3):840-9.
17. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu RA, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89(10):3534-43.
18. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111(3):1534-42.
19. Tiu RV, Gondek LP, O'Keefe CL, Huh J, Sekeres MA, McDevitt M, et al. New lesions detected by SNP array-based chromosomal analysis have important clinical impact in AML. J Clin Oncol. 2009; 27(31):5219-26.
20. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96(12):3671-4.
21. Schnittger S, Meggendorfer M, Kohlmann A, Grossman V, Yoshida K, Ogawa S, et al. SRSF2 is mutated in 47.2% (77/163) of chronic myelomonocytic leukemia (CMML) and prognostically favorable in cases with concomitant RUNX1 mutations. Blood. 2011;118(21):274 [abstract].
22. Traina F, Jankowska AM, Visconte V, Sugimoto Y, Szpurka H, Makishima H, et al. Impact of molecular mutations on treatment response to hypomethylating agents in MDS. Blood. 2011;118(21):213 [abstract].
23. Graubert TA, Shen D, Ding L, Okeyo Owuor T, Lunn CL, Shao J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011;44(1):53-7.
24. Yoshida N, Yagasaki H, Xu Y, Matsuda K, Yoshimi A, Takahashi Y, et al. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Pediatr Res. 2009;65(3):334-40.
25. Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010; 10:401.
26. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239-46.
27. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Al-Kali A, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2011;118(21):213 [abstract].
28. Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12): 1676-81.
29. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788-800.
30. Parkin B, Erba H, Ouillette P, Roulston D, Purkayastha A, Karp J, et al. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood. 2010;116(23):4958-67.
31. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2011;119(9): 2114-21.
32. Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep 2011;6(2):126-35.
33. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17(9): 2613-8.
34. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-506.
35. Makishima H, Cazzolli H, Dunbar A, Muramatsu H, O'Keefe CL, Hsi E, et al. Mutations of E3 ubiquitin ligase Cbl family members constitue a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009;27(36):6109-16.
36. Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15): 1971-9.
37. He C, Zhou F, Zuo Z, Cheng H, Zhou R. A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis. PLoS ONE. 2009;4(3):e4732.
38. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8(4):349-57.
39. Brinkman BM, Wong DT. Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol. 2006;18(3): 228-33.
40. Hirabayashi S, Flotho C, Moetter J, Heuser M, Hasle H, Gruhn B, et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood. 2012;119(11):e96-e9.